Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant viruses and tumors in the United States. The company is headquartered in Houston, Texas.
52W High
$3.33
52W Low
$0.25
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.50
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.52
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
476.20
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
3.52%
Institutions (25–75% balanced)
6.67%
Shares Outstanding
30,286,200
Float
27,650,400
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-3.74
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-5.04%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—